🔗 Share this article

While America undertakes historic changes to its vaccination recommendations, a particular individual has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports physician and public health researcher who first made her name by casting doubt on Covid shots in the global health crisis and has concentrated on potential deaths after Covid vaccination in her recent time at the FDA.

Proposed Changes to Pediatric Vaccine Program

Public health authorities were set to announce major revisions to the pediatric vaccination calendar earlier this month, synchronizing the US with the Danish vaccine program, according to reports – a major change that would place the US out of alignment with many the international standard with insufficient data for benefit. The announcement has been pushed back until the coming year.

In place of the director of the vaccine center, Dr. Høeg is set to speak at the meeting. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth individual to head the division this year.

Consolidating Power at the Agency

Høeg's temporary position might represent a tighter collaboration between the drug and vaccine centers as Høeg and Dr. Prasad solidify control at the regulatory agency – and it suggests a increased emphasis upon rolling back already-approved immunizations at the FDA.

Dr. Høeg has often pushed for halting certain pediatric vaccine recommendations in the US so as to align more similar to Denmark, a society with nationalized medicine and a population about the size of the state of Wisconsin.

To date public appearances, she has continued to focus on immunizations – usually the purview of Dr. Prasad, chief of the FDA’s vaccine center – as opposed to drug regulation.

Concerns Over Background

The appointee has no obvious track record in medication creation, oversight or management, which has been typical for former leaders of the biologics center. She has worked at the FDA as a top consultant to the FDA chief and CBER since March.

“She appears not to have the requisite experience” for running the pharmaceutical oversight division, said a neurologist and psychiatrist. “She has not conducted a scientific study. She lacks experience in running a major agency. She lacks background in drug approvals.”

Previous commissioners of CBER would “understand laws and regulations and the underlying principles of medication creation”, said a former acting FDA commissioner. “Objectively, she has not acquired the sort of resume that former directors who led CBER have had.”

The drug center has an enormous range of responsibilities at the agency, the former commissioner stated.

“Many people just focuses on the innovative therapies, but the off-patent medication office clears a multitude of generic drugs. There’s a biosimilars program, non-prescription drug unit and so forth, and all of those have to be supervised,” she explained. “The thing you overlook, that’s the thing that I always told people is going to bite you.”

There is also, a significant leadership component to the role, which manages over 5,000 staff members. “It’s a huge management job, if you do it right,” Woodcock concluded.

Response and Controversial Programs

When asked about concerns about Høeg’s qualifications and whether this selection signifies increased cooperation among regulatory chiefs on vaccines, a press secretary said that the “questions are based on inaccurate premises”.

“This background matches the duties of her role,” the representative stated, noting the time Høeg spent counseling the agency head on “medication safety and approval science, including computational safety modeling and shot safety tracking”.

In her interim role, Høeg takes over the commissioner’s controversial expedited review system, a contentious rapid therapy clearance system that allegedly troubled her former heads. “How are these therapies being picked for this voucher program? Who is making the calls?” Dr. Howard questioned. “There’s a lot of secrecy occurring at the agency right now.”

Overall, he stated, “the Food and Drug Administration looks to be trending towards more relaxed regulations of most medications, with the exception of vaccines.”

Established Track Record on Vaccines

Regarding immunizations, Høeg has a clearer, if troubling, history, critics observe. She released a analysis using non-validated volunteer-provided data to determine the incidence of heart inflammation after COVID-19 vaccination. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who allegedly have changed statistics to imply COVID-19 vaccines are more dangerous than they are.

Included in her “wish list” for the current administration featured revising regulations for new vaccines and halting “unnecessary” immunizations, she remarked after the election on a audio program. At the FDA, Dr. Høeg has reportedly floated the idea of preventing adolescent males from obtaining COVID-19 vaccines.

“She’s an complete ideologue who begins with her beliefs and tailors the evidence to retrofit the evidence in a highly misleading, dishonest fashion,” Dr. Howard argued.

Taking Control and a “Campaign of Retribution”

Høeg became part of other contrarians, {like|